Discover the potential of cannabidiol (CBD) in diabetes control
Research shows that cannabis compounds, such as CBD and THCV, can help with glycemic control, insulin resistance, and relief of neuropathic pain in diabetes patients
Diabetes is a chronic disease characterized by high levels of glucose in the blood. The condition occurs when the body fails to produce or properly use insulin, a key hormone produced by the pancreas to control sugar levels after eating. Without this balance, excess glucose in the bloodstream can be toxic.
Among the most common types of the disease are type 1 diabetes, type 2 diabetes, gestational diabetes, and prediabetes. With the growth of research on alternative therapies, scientists have been investigating the role of cannabis compounds, especially cannabidiol (CBD), in the treatment of metabolic diseases.
A pioneering study from 2006, conducted by Raphael Mechoulam — a world reference in cannabis research — at the Hebrew University of Jerusalem, showed promising results. Published on platforms like ResearchGate and PubMed, the work titled "Cannabidiol reduces the incidence of diabetes in non-obese diabetic mice" revealed that CBD significantly reduced the incidence of the disease: from 86% in mice treated with placebo to only 30% in those that received the cannabinoid.
Related Articles:
PubMed - CBD and Diabetes
The American Journal of Medicine - CBD and metabolism
See more article here
Another article, published by the Mexican Journal of Forensic Medicine in 2019, also suggests that CBD can contribute to metabolic balance. According to the publication, the endocannabinoid system, along with the endocrine system, plays a role in regulating body energy. When dysregulated, it can contribute to dysfunctions such as dyslipidemia, obesity, and type 2 diabetes. In this context, CBD — in controlled doses prescribed by a professional — stands out for its anti-inflammatory properties, aiding in disease control.
Studies indicate that CBD can positively influence glycemic control. In a double-blind clinical trial conducted by Jadoon et al. (2016) with type 2 diabetes patients, it was observed that CBD reduced insulin resistance and increased levels of glucose-dependent insulinotropic peptide. Another cannabinoid, THCV, showed a significant reduction in fasting glucose and improvement in pancreatic beta cell function and insulin sensitivity.
Chronic pain — especially diabetic peripheral neuropathy — can also benefit from medical cannabis. A study with 800 patients with refractory neuropathic pain showed that the THC:CBD combination brought significant relief, especially in cases of pain with neurological signs. Patients with nociceptive pain showed a lower response and high treatment dropout rates.
Another experiment with diabetic rats showed that CBD reduced mechanical allodynia (exaggerated pain sensitivity) by activating the 5-HT1A receptor, linked to serotonin, and not through the traditional CB1 and CB2 receptors — expanding the understanding of CBD's therapeutic potential.
The role of the endocannabinoid system in metabolism
The endocannabinoid system (ECS) plays a fundamental role in regulating energy metabolism, food behavior, insulin secretion, and glycemic homeostasis. It consists of CB1 and CB2 receptors, molecules like anandamide (AEA) and 2-AG, and enzymes responsible for its regulation.
Activation of CB1 receptors, mainly in the central nervous system, stimulates appetite and fat storage. However, its overactivation in peripheral tissues such as the liver and adipose tissue is associated with increased lipogenesis, insulin resistance, and the development of type 2 diabetes. Studies show that patients with metabolic disorders have a dysregulated ECS, making it a promising therapeutic target.
In the pancreas, the ECS regulates insulin release by beta cells. In adipose tissue, it influences insulin sensitivity and processes like adipogenesis and thermogenesis. In the liver, its dysregulation contributes to fat accumulation and hepatic steatosis — conditions closely linked to insulin resistance.